Eli Lilly (LLY +1.3%) announces positive
long-term data from a study evaluating Olumiant (baricitinib) in
patients with moderate-to-severe rheumatoid arthritis (RA) who were
treated for three years. The results were virtually presented at EULAR.
52% of patients who failed to respond adequately
to methotrexate who responded to Olumiant therapy by week 24 maintained
their responses through week 148.
No new safety signals were reported from 3,770 patients treated with Olumiant for up to 8.4 years.
The FDA approved the JAK inhibitor for RA in June 2018.
https://seekingalpha.com/news/3582063-lillys-baricitinib-shows-sustained-benefit-in-rheumatoid-arthritis-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.